

Management Discussion and Analysis
(Expressed in Canadian Dollars)

KANE BIOTECH INC.

Six months ended June 30, 2018 and 2017

KANE BIOTECH INC.

Management Discussion and Analysis

The following management discussion and analysis ("MD&A") covers information up to August 21, 2018 and should be read in conjunction with the interim financial statements for the period ended June 30, 2018. Except as otherwise noted, the financial information contained in this MD&A and in the financial statements has been prepared in accordance with IFRS. All amounts are expressed in Canadian Dollars unless otherwise noted. Additional information regarding the Company is available on SEDAR at www.sedar.com and on the Company's website at www.kanebiotech.com.

This MD&A has been prepared to help investors understand the financial performance of the Company in the broader context of the Company's strategic direction, the risks and opportunities as understood by management, and the key success factors that are relevant to the Company's performance. Management has prepared this document in conjunction with its broader responsibilities for the accuracy and reliability of the financial statements, as well as the development and maintenance of appropriate information systems and internal controls to ensure that the financial information is complete and reliable. The Audit Committee of the Board of Directors has reviewed this document and all other publicly reported financial information for integrity, usefulness, reliability and consistency.

FORWARD-LOOKING STATEMENTS

This Management's Discussion and Analysis contains certain forward-looking information and statements within the meaning of securities law which may not be based on historical fact, including without limitation statements containing the words "believes," "should", "may," "plan," "will," "estimate," "predict," "continue," "anticipates," "potential", "intends," "expects," or other similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the Company's stage of development, lack of product revenues, additional capital requirements, risks associated with the completion of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property and dependence upon collaborative partners. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements are made as of the date hereof, and the Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.

Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this MD&A. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about:

- general business and economic conditions;
- interest rates and foreign exchange rates;
- the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects;
- the availability of financing for the Company's research and development projects, or the availability of financing on reasonable terms;
- the Company's costs of trials;
- the Company's ability to attract and retain skilled staff;
- market competition;
- tax benefits and tax rates;
- the Company's ongoing relations with its employees and with its business partners.

Management cautions you, the reader, that the foregoing list of important factors and assumptions is not exhaustive. Events or circumstances could cause actual results to differ materially from those estimated or projected and expressed in, or implied by, these forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, whether as a result of new information or future events or otherwise

KANE BIOTECH INC.

Management Discussion and Analysis

OVERVIEW

Kane Biotech Inc. (“Kane Biotech” or the “Company”) is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. Biofilms are thin slimy films that develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. Biofilms attach to and grow on living and inert surfaces. When in a biofilm, bacteria become highly resistant to antibiotics, antimicrobials, biocides and host immune responses. This resiliency contributes to numerous human and animal health related problems. According to the United States National Institutes of Health, biofilms are estimated to be responsible for 80% of all animal and human bacterial infections including tooth decay, wound care infections, chronic inflammatory skin disorders and wounds, recurrent urinary tract infections, medical device associated and hospital acquired infections (HAIs), and foodborne bacterial outbreaks. Biofilms cost society billions of dollars each year. As such, there is significant interest in safe and effective products that can combat the biofilm problem. Kane Biotech’s mission is to be a royalty-based revenue company licensing its anti-biofilm technologies to global industry players.

Key Highlights of Kane Biotech include the following:

- A specialized focus on large markets for biofilm prevention and dispersion solutions
- Strong patent portfolio of anti-biofilm technologies with 75 patents and patents pending
- First commercial licensing and distribution agreement signed (2017)
- Several anti-biofilm applications in development for large market opportunities

Kane Biotech has a portfolio of biotechnologies, intellectual property (patents, patents pending and trademarks) and products developed by the Company’s own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, bluestem®, AloSera™, coactiv+™ and coactiv+® are trademarks of Kane Biotech Inc.

The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol "KNBIF".

COMPANY FOCUS

Over the past year Kane Biotech has focused the majority of its resources on applications of its technology on oral care and skin care in the companion pet market, human skin disorders, and the disinfection of hard surfaces. Kane Biotech’s objective is to license the Company’s intellectual property to strategic partners with already established large scale market and territory access. Kane Biotech’s premium companion pet oral care products, StrixNB™ and bluestem™, are targeted at multiple channels, including veterinary clinics, pet specialty retail, grocery/mass merchants, and e-commerce. DispersinB® is a powerful biofilm dispersion enzyme with initial targeted applications for canines which include otic ear infections and skin “hot spot” infections. A shampoo that fights atopic dermatitis on dogs has been formulated and is ready for in-vivo testing and test marketing. The Company’s StrixNB and DispersinB technologies are licensed to Dechra Veterinary Products LLC (“Dechra”), a wholly-owned subsidiary of Dechra Pharmaceuticals PLC (LSE:DPH) for marketing and distribution in the North American veterinary channel. Dechra markets the StrixNB™ technology under its Vetrudent™ brand name. More information about the Dechra agreement is provided below.

For human health skin disorder conditions, Kane Biotech has several formulations in final development based on its proprietary anti-biofilm technologies that have the potential to treat conditions such as athlete’s foot, eczema and seborrheic dermatitis. Athlete’s foot afflicts 15% of the world population and its global market is estimated to be almost \$1B. Eczema (atopic dermatitis) afflicts 10% of adults and 25% of children globally and by 2022 its global market is estimated will reach \$5.6B. Seborrheic dermatitis (including chronic dandruff) is the fastest growing hair care segment and by 2020 its size is projected will reach \$6B. In-vitro data as well as testimonials of people using Kane Biotech’s formulations for these three conditions have been strong and compelling. The Company plans to gather clinical data in 2018 on the application of its technology to these conditions to help advance discussions with potential market partners.

Kane Biotech’s antimicrobial and anti-biofilm hard surface disinfectant technology has applications in hospitals, medical device decontamination, food production and safety, and industrial process control environments where highly resistant bacteria can cause major problems. Further work on formulations and their testing of this technology will continue in 2018.

Targeted company milestones for 2018 include the following:

- Uplist to OTCQB Venture Market (January 2018)
- Retain investor relations counsel (February 2018)
- File lawsuit against Nestlé to defend Kane Biotech’s intellectual property (February 2018)
- Existing license expansion for companion animal veterinary market in terms of geography and product applications

KANE BIOTECH INC.

Management Discussion and Analysis

- Complete additional trials and achieve International standard of canine oral care efficacy
- Launch DispersinB® based products with Dechra
- Execute new technology license and distribution agreements
- Initiate clinical trials for technologies treating human chronic inflammatory skin disorders

SUMMARY OF 2018 KANE BIOTECH PRESS RELEASES UP TO AUGUST 21, 2018

On August 21, 2018, the Company announced its Second Quarter 2018 Financial Results.

On August 15, 2018, the Company announced it scheduled its Second Quarter Earnings Conference Call and Business Update on Wednesday, August 22, 2018 at 4:30pm E.T. to discuss its financial results for the second quarter, in conjunction with the filing of its Financial Statements for the second quarter ended June 30, 2018.

On August 14, 2018, the Company announced that it had secured eligibility by The Depository Trust Company ("DTC") for its shares on the OTCQB Venture Market. DTC eligibility will simplify the process of trading and is expected to enhance liquidity of the Corporation's common shares on the OTC marketplace where Kane Biotech trades under the symbol "KNBIF".

On August 9, 2018, the Company announced the engagement of Dave D. Hood, President and Chief Executive Officer of DH3 & Associates, as a strategic consultant to help secure non-dilutive funding opportunities through government research or industry grants, foundations, industry partnerships and other avenues.

On July 31, 2018, the Company announced that a three-year Cooperative Research and Development Agreement (CRADA) extension has been signed with the U.S. Army Institute of Surgical Research (USAISR) in Fort Sam Houston, Texas. The primary objective of this collaboration on "Treatments to Prevent Biofilm Formation for Promoting Wound Healing" is to develop an antibiofilm-antimicrobial wound gel formulation and test the said gel formulation to address the needs of the United States Army Dental and Trauma Research Detachment's (USADTRD) programs and that can be readily translated into clinical testing for improving the outcomes of wounded casualties.

On July 24, 2018, the Company announced it had, subject to regulatory approval, agreed to retain Venture Liquidity Providers Inc. to initiate its market-making service to provide assistance in maintaining an orderly trading market for the common shares of the Corporation. The market-making service will be undertaken by VLP through a registered broker, W.D. Latimer Co. Ltd., in compliance with the applicable policies of the TSX Venture Exchange and other applicable laws.

On July 17, 2018, the Company announced that it had received a loan in the amount of \$500,000 from Individual Investment Corporation, an arm's length third-party lender. The loan bears interest at 12% per annum and is repayable after six months. Additional consideration for the loan guarantee was the issuance of 3,500,000 share purchase warrants at a price of \$0.08 per common share for a period of one year from the date of issuance of the warrants. The Company will use the proceeds of the loan for general working capital to continue its operations.

On June 21, 2018, the Company announced that it would be attending SuperZoo, North America's leading pet retail trade exposition and conference, taking place June 26-28, 2018 at the Mandalay Bay Convention Center in Las Vegas, NV. Mark Ahrens-Townsend, Chief Executive Officer of Kane Biotech, along with key members of the Kane Biotech team attended the conference to showcase Kane Biotech's bluestem™ brand of premium pet oral care products and to highlight their new bluestem™ skin care shampoo for dogs and cats.

On June 14, 2018, the Company announced that it would present at The MicroCap Conference being held in Toronto on June 21, 2018. Mark Ahrens-Townsend, President & CEO of Kane Biotech, presented and met with investors attending the conference.

On June 1, 2018, the Company announced that it would be attending the 2018 BIO International Convention being held June 4-7, 2018 at the Boston Convention Center in Boston, MA. showcasing the Company's technologies and products that break up bacterial biofilm in the human, animal, commercial, institutional and industrial sectors. Kane Biotech management participated in meetings with potential clinical and commercial partners, investors and other parties at their booth and in the Business Forum.

On May 31, 2018, the Company announced it has been granted a significant patent in the area of wound care by the U.S. Patent and Trademark Office (the "USPTO"). The patent is titled "Antimicrobial-Antibiofilm Compositions And Methods Of Use Thereof".

On May 24, 2018, the Company announced that it would present at the TakeStock! Investor Forum being held in Calgary, Alberta on May 31, 2018. Mark Ahrens-Townsend, Chief Executive Officer of Kane Biotech, presented and met with investors attending

KANE BIOTECH INC.

Management Discussion and Analysis

the conference.

On May 22, 2018, the Company announced the appointment of pharmaceutical executive Rashieda Gluck to its Board of Directors. With over 20 years of experience in the global pharmaceutical, biotechnology, and life science industries, Ms. Gluck's career has spanned all levels and functions in clinical development. As an executive, her focus has been on leading the strategic planning and successful implementation of high quality clinical development programs.

On May 17, 2018, the Company announced its First Quarter 2018 Financial Results, Granting of Options and Investor Relations Improvements.

On May 10, 2018, the Company announced it scheduled its First Quarter Earnings Conference Call and Business Update on Friday, May 18, 2018 at 8:30am E.T. to discuss its financial results for the first quarter, in conjunction with the filing of its Financial Statements for the first quarter ended March 31, 2018.

On April 5, 2018, the Company announced that it would present at the MicroCap Conference being held in New York, NY from April 9-10, 2018 with Mark Ahrens-Townsend, Chief Executive Officer of Kane Biotech, giving a presentation and meeting with investors attending the conference.

On March 21, 2018, the Company announced its 2017 Year End and Fourth Quarter Financial Results and Business Update.

On March 20, 2018, the Company announced that for the third consecutive year it will be attending the 14th Annual Global Pet Expo being held on March 21-23, 2018 at the Orange County Convention Center in Orlando, Florida. It will be attending the Expo to help showcase Kane Biotech's bluestem™ brand of premium pet oral care products and to introduce the Company's new bluestem skin care shampoo for dogs and cats.

On March 16, 2018, the Company announced its scheduled its Fourth Quarter and Full Year 2017 Earnings Conference Call and Business Update on Thursday, March 22, 2018 at 4:30pm E.T. to discuss its financial results for the fourth quarter and full year 2017, in conjunction with the filing of its annual Year End Financial Statements for the fourth quarter and full year ended December 31, 2017.

On February 26, 2018, the Company announced that it filed a lawsuit against Nestec, Ltd., a/k/a Nestec, S.A. ("Nestec"), and Nestlé Purina Petcare Global Resources, Inc. ("Nestlé Purina"), (collectively "Nestlé") for breach of agreements between the parties, and misappropriation of Kane Biotech's trade secrets and intellectual property.

On February 1, 2018, the Company announced that it retained Edison Advisors, a global strategic advisory firm, as the Corporation's investor relations counsel. Edison has been engaged to provide investor relations services to Kane Biotech as it works towards its mission to be a global leader in creating innovative technologies for licensing and product commercialization that breakdown and disperse biofilms.

On January 31, 2018, the Company announced that its shares were approved for and will commence trading on the OTCQB Venture Market, operated by OTC Markets Group under the symbol "KNBIF".

INTELLECTUAL PROPERTY

Patent #	Title	Jurisdiction
2,452,032	Synergistic Antimicrobial Compositions and Methods of Inhibiting Biofilm Formation	Canada
7,314,857	Synergistic Antimicrobial Compositions and Methods of Inhibiting Biofilm Formation	United States
7,144,992	Synergistic Antimicrobial Compositions and Methods for Reducing Biofilm Formation	United States
8,906,364	Antimicrobial Compositions for Inhibiting Growth and Proliferation of Microbial Biofilms	United States
2,006,265,707	Antimicrobial Compositions for Inhibiting Growth and Proliferation of Microbial Biofilms	Australia
2,612,729	Antimicrobial Compositions for Inhibiting Growth and Proliferation of Microbial Biofilms	Canada
ZL 200680024157.1	Antimicrobial Compositions for Inhibiting Growth and Proliferation of Microbial Biofilm	China
EP1906736	Antimicrobial Compositions for Inhibiting Growth and Proliferation of Microbial Biofilms	Europe
286291	Antimicrobial Compositions for Inhibiting Growth and Proliferation of Microbial Biofilms	India
4999842	Antimicrobial Compositions for Inhibiting Growth and Proliferation of Microbial Biofilms	Japan

KANE BIOTECH INC.

Management Discussion and Analysis

564904	Antimicrobial Compositions for Inhibiting Growth and Proliferation of Microbial Biofilms	New Zealand
EP1906736	Antimicrobial Compositions for Inhibiting Growth and Proliferation of Microbial Biofilms	Germany
EP1906736	Antimicrobial Compositions for Inhibiting Growth and Proliferation of Microbial Biofilms	France
EP1906736	Antimicrobial Compositions for Inhibiting Growth and Proliferation of Microbial Biofilms	United Kingdom
6,923,962	Signal Peptides, Nucleic Acid Molecules and Methods for Treatment of Caries	United States
7,597,895	Signal Peptides, Nucleic Acid Molecules and Methods for Treatment of Caries	United States
7,294,497	Compositions and Methods for Enzymatic Detachment of Bacterial and Fungal Biofilms	United States
540731	Compositions and Methods for Enzymatic Detachment of Bacterial and Fungal Biofilms	New Zealand
555378	Compositions and Methods for Enzymatic Detachment of Bacterial and Fungal Biofilms	New Zealand
2,003,284,385	Compositions and Methods for Enzymatic Detachment of Bacterial and Fungal Biofilms	Australia
7,833,523	Compositions and Methods for Enzymatic Detachment of Bacterial and Fungal Biofilms	United States
7,989,604	Compositions and Methods for Enzymatic Detachment of Bacterial and Fungal Biofilms	United States
5,073,169	Compositions and Methods for Enzymatic Detachment of Bacterial and Fungal Biofilms	Japan
8,580,551	Dispersin B Polypeptides and uses thereof	United States
8,821,862	Soluble β -N-Acetylglucosaminidase Based Antibiofilm Compositions and Uses Thereof	United States
8,617,542	Dispersin B, 5-Fluorouracil, Deoxyribonuclease I and ProteinaseK-Based Antibiofilm Compositions and uses thereof	United States
2,720,301	Dispersin B, 5-Fluorouracil, Deoxyribonuclease I and ProteinaseK-Based Antibiofilm Compositions and uses thereof	Canada
EP2283130	Dispersin B, 5-Fluorouracil, Deoxyribonuclease I and ProteinaseK-Based Antibiofilm Compositions and uses thereof	Europe
EP2283130	Dispersin B, 5-Fluorouracil, Deoxyribonuclease I and ProteinaseK-Based Antibiofilm Compositions and uses thereof	United Kingdom
EP2283130	Dispersin B, 5-Fluorouracil, Deoxyribonuclease I and ProteinaseK-Based Antibiofilm Compositions and uses thereof	Germany
EP2283130	Dispersin B, 5-Fluorouracil, Deoxyribonuclease I and ProteinaseK-Based Antibiofilm Compositions and uses thereof	France
8,753,692	Biofilm-Removing Antimicrobial Compositions and uses thereof	United States
2,750,340	Biofilm-Removing Antimicrobial Compositions and uses thereof	Canada
5,752,051	Biofilm-Removing Antimicrobial Compositions and uses thereof	Japan
EP2389071	Biofilm-Removing Antimicrobial Compositions and uses thereof	Europe
EP2389071	Biofilm-Removing Antimicrobial Compositions and uses thereof	United Kingdom
EP2389071	Biofilm-Removing Antimicrobial Compositions and uses thereof	Germany
EP2389071	Biofilm-Removing Antimicrobial Compositions and uses thereof	France
9,622,481	Biofilm-Removing Antimicrobial Compositions and uses thereof	United States
2012332014	Compositions and Methods for Treatment and Prevention of Oral Diseases	Australia
6,038,167	Compositions and Methods for Treatment and Prevention of Oral Diseases	Japan
624,850	Compositions and Methods for Treatment and Prevention of Oral Diseases	New Zealand
9,980,497	Compositions and Methods for Treatment and Prevention of Wound Infections	United States

The Company has 43 issued and 32 pending patents. Successful development of products to prevent and remove microbial biofilms may be dependent upon the ability to obtain these patents; however, there is no guarantee they will be obtained, and, if obtained, it may not be possible to successfully defend against any subsequent infringements to these patents. Currently the Company is unaware that it has infringed upon any existing patents issued to third parties and success may, in part, depend on operating without such infringement.

Trademark	Jurisdiction
DispersinB®	Canada United States Europe United Kingdom
StrixNB™	Canada Europe Canada
Aledex™	Canada
Aledex®	United States
bluestem™	Canada United States
bluestem®	United States Europe

KANE BIOTECH INC.

Management Discussion and Analysis

AloSera™

Coactiv+™

Coactiv+®

Canada
United States
Canada
United States
Europe

KANE BIOTECH TECHNOLOGIES

StrixNB™ and bluestem

The Company's trademarks for the companion pet oral care market are StrixNB™, bluestem® and bluestem™. The companion pet oral care market in the U.S. was estimated to be \$775 million in 2015 and is projected to grow to nearly \$1 billion by 2020. According to the American Veterinary Medical Association (AVMA) oral health is one of the top three concerns for companion animal owners. Bacteria in the mouth cavity form plaque and as the plaque grows this causes tartar build-up, gum infection (gingivitis) and periodontitis. By the time they are three years old 80% of dogs and 70% of cats develop some sort of periodontal disease.

The Company introduced its companion pet oral care products in Canada under the StrixNB and bluestem brands and received Health Canada's Low Risk Veterinary Health Products (known as LRVHP) which Health Canada recently replaced with the Veterinary Health Products (VHP) - Notification Program. Approvals under these programs are in place for oral care liquid water additives, a water additive powder formulation, an oral spray formulation and a toothpaste. The Company pursued a strategy to license out its intellectual property on a broader scale which led to Kane Biotech's StrixNB technology and trademarks being part of a 10-year exclusive licensing and distribution agreement with Dechra Veterinary Products LLC for the North American veterinary market announced March 6, 2017. Dechra introduced its Vetradent™ oral care brand into the U.S. and Canadian veterinary channel in Q4, 2017. In conjunction with Dechra, additional formulations are in development to expand Dechra's complete oral health program of pet oral care products for veterinary clinics and dog and cat parents. A dental wipe was added to the Vetradent product family in Q2, 2018. A dental treat and rawhide chew are in development for market release later this year.

Kane Biotech's bluestem brand of products are sold in approximately 900 pet specialty retail stores in Canada and the U.S., as well as Amazon.com (U.S.) and Amazon.ca (Canada) Based on the Company's science, efficacy, safety and value the bluestem products are well received in the market. In line with the Company's licensing strategy, Kane Biotech intends to license the bluestem brand and technology to a partner with significant market access for the pet specialty, grocery mass and internet e-commerce markets.

DispersinB® and AloSera™

The Company's trademarks for the wound care market are DispersinB® for animal and human wound care applications and AloSera™ shampoo for the treatment of atopic dermatitis in canines. The current global market for human wound care management technology is estimated at \$4.5 billion USD per year. The size of the market for atopic dermatitis for dogs is difficult to determine. One product, Apoquel™, a veterinary immune system suppressant medication used in the control of atopic dermatitis and pruritus (itchiness) from allergic dermatitis in dogs, is rumored to have had \$250 million USD in sales during 2017. Kane Biotech has topical formulations in development for both the animal health (canines) and the human health markets.

The Company has three products approved. A topical spray for atopic dermatitis-associated infections for veterinary use, which has Health Canada's Interim Notification Program for Low Risk Veterinary Health Products (LRVHP) approval and two dermatological products approved by Health Canada's Natural Health Product Directorate for human use; a skin care cream that treats eczema and a shampoo that treats seborrheic dermatitis and chronic dandruff. Final formulations are being tweaked and the Company plans modest scale clinical trials this year to support positive testimonials of people who have used the products.

The Company has started to pursue its strategy to license out its wound care intellectual property on a broader scale. Kane Biotech's DispersinB technology and trademarks were part of the 10-year exclusive licensing and distribution agreement with Dechra Veterinary Products LLC announced March 6, 2017. Introduction of DispersinB products for canine otic (ear) infections in conjunction with Dechra is targeted for late-2018. Additional DispersinB and AloSera based products are in development.

KANE BIOTECH INC.

Management Discussion and Analysis

Aledex®

The Company's trademark for the medical device coating market is Aledex®. Kane Biotech has both in vitro and in vivo data that demonstrates the product's ability to inhibit the activity of numerous catheter associated pathogens and protect against urinary catheter related infections. Approximately 30 million urethral catheters are sold in North America annually and indwelling urinary catheters are used in approximately 15% to 25% of short term care patients and all patients in intensive care units. Additionally, in the U.S. alone, more than 150 million intravascular catheters are used and over 5 million central venous lines are inserted. This results in about 250,000 catheter related infections each year.

Kane Biotech supplied Aledex for the coating of catheters as the positive control for a collaborative effort between the Center for Biofilm Engineering – Montana State University (www.biofilm.montana.edu) and the FDA to develop and validate an in vitro method to test the ability of surface modified urinary catheters to prevent and/or delay biofilm development and reduce the risk of bacterial infections. The research is being funded by the Burroughs Wellcome Foundation (www.bwfund.org).

KBI Disinfectant Technology

KBI Antibacterial Disinfectant was issued a Drug Identification Number or DIN (02374463) in 2011 by the Therapeutic Products Directorate of Health Canada as a hard surface disinfectant for use in domestic, hospital, and industrial environments. The Company is continuing its efforts in the research and development of these disinfectant technologies in pursuit of further antimicrobial and anti-biofilm claims.

OUTLOOK

The strategic direction of the Company is centered on developing and commercializing solutions to biofilm related problems. To advance these programs, management expects Kane Biotech to continue incurring operating losses in the foreseeable future. Based on current projections, but depending on timing, total revenue is expected to increase in fiscal 2018 as compared to fiscal 2017. Net expenses in 2018 are expected to be lower compared to fiscal 2017.

The Company's funding of future operations is dependent upon its ability to negotiate collaboration or licence royalty agreements with upfront and subsequent milestone payments, generate product sales, obtain research grant funding, and/or secure additional funds. While the Company is striving to achieve funding through the above-mentioned alternatives, there is no assurance that such sources will be available or obtained on favourable terms. If the Company cannot realize sufficient funding from these sources, it will have to consider additional strategic alternatives which may include, among other strategies, exploring the monetization of certain tangible and intangible assets as well as seeking to license assets or potential asset divestitures.

The ability of the Company to continue as a going concern and to realize the carrying value of its assets and discharge its liabilities and commitments when due is dependent on the successful completion of the actions taken or planned, some of which are described above, which management believes will mitigate the adverse conditions and events which raise doubt about the validity of the going concern assumption used in preparing its financial statements. There is no certainty that these and other strategies will be sufficient to permit the Company to continue as a going concern.

The Company may decide to accelerate, terminate or reduce its focus in certain research areas, or commence research in new areas as a result of the Company's research progress and the availability of financial resources. These decisions are made with the goals of managing the Company's cash resources and optimizing the Company's opportunities. Management is not presently aware of any factors that would change its strategy over the next year. See also "Note 2(c) Going concern" to the accompanying financial statements.

SELECTED QUARTERLY FINANCIAL INFORMATION

The selected financial information provided below is derived from Kane Biotech's unaudited quarterly financial statements for each of the last eight quarters:

KANE BIOTECH INC.

Management Discussion and Analysis

	Q2-2018	Q1-2018	Q4-2017	Q3-2017	Q2-2017	Q1-2017	Q4-2016	Q3-2016
	\$	\$	\$	\$	\$	\$	\$	\$
License	-	-	-	-	-	670,725	-	-
Royalty	9,218	13,097	9,672	4,480	3,355	-	-	-
Sales of goods and services	86,592	80,113	73,997	56,247	102,651	114,175	74,619	59,278
Total Revenue	95,810	93,210	83,669	60,727	106,006	784,900	74,619	59,278
Cost of Sales	24,154	39,384	37,545	14,542	33,432	36,885	42,416	31,317
Gross Profit	71,656	53,826	46,125	46,185	72,574	748,015	32,203	27,961
Operating Expenses	771,716	942,890	934,565	910,168	803,989	959,135	508,576	625,486
Loss for the Qtr	(701,714)	(889,796)	(888,686)	(869,246)	(790,549)	(237,692)	(500,057)	(616,063)
Loss per share	(0.01)	(0.01)	(0.01)	(0.01)	(0.02)	(0.01)	(0.01)	(0.01)

It is important to note that historical patterns of expenditures cannot be taken as an indication of future expenditures. The amount and timing of expenditures, and therefore liquidity and capital resources, may vary substantially from period to period depending on the business and research activities being undertaken at any one time and the availability of funding from investors and prospective commercial partners.

The Company's ongoing operating expenses relate primarily to the execution of research programs, the commercialization of its intellectual property and general and administrative expenses. The operations of the Company are not subject to any material seasonality or cyclical factors.

Dechra licensed the Company's StrixNB products and technology for the North American companion pet veterinary market commencing in early March 2017. The Company's StrixNB product revenues were significantly reduced once Dechra moved to its own brand (Vetradent) sourced from its own contract manufacturer. As Dechra increases its sales of Vetradent in Canada, the United States and Mexico, Kane Biotech expects to receive increasing royalty payments. The Company retains the ability to sell StrixNB outside of North America and is pursuing options for licensing in Europe, Asia and other geographies. International sales of StrixNB have been modest since the signing of the licensing agreement with Dechra.

Total operating expenses in earlier quarters included higher product marketing spending than in more recent quarters reflecting the subsequent licensing of StrixNB to Dechra and recently reduced spending on bluestem marketing. Previous quarters up to and including Q1, 2018 include significant spending on contract research. The first and second quarters of 2018 included legal expenses pertaining to the Nestle lawsuit which were not incurred in earlier quarters as well as higher investor relations costs and costs associated with uplisting to the OTCQB Venture Market.

RESULTS OF OPERATIONS

Revenue

Revenue consists of License and Royalty revenue from its licensing agreement with Dechra, product sales from the Company's bluestem and StrixNB brands and contract manufacturing and quality control services revenue related to the Company's relationship with Dechra.

The Company's revenue by category for the three months ended June 30, 2018 and 2017 is summarized in the table below:

Three months ended June 30,	2018	2017	Change	% Change
Royalty	\$ 9,218	\$ 3,355	\$ 5,863	174.7%
Sales of goods and services	86,592	102,651	(16,059)	-15.6%
Total Revenue	\$ 95,810	\$ 106,006	\$ (10,196)	-9.6%

Royalty revenue consists of royalties received from Dechra on their sales of Vetradent products in the North American veterinary market. In the three months ended June 30, 2018, royalty payments received from Dechra increased by 175% to \$9,218 compared to \$3,355 in the three months ended June 30, 2017 as Dechra continues to roll out the Vetradent product line to its North American veterinarian customer base.

KANE BIOTECH INC.

Management Discussion and Analysis

Revenue from the sales of goods and services (bluestem, StrixNB, contract manufacturing and contract quality control services) in the three months ended June 30, 2018 was \$86,592, a decrease of 16% compared to \$102,651 in the three months ended June 30, 2017. During the three months ended June 30, 2017, the Company had not yet fully transitioned the licensure of its StrixNB technology to Dechra. StrixNB product revenue in the three months ended June 30, 2017 was \$48,389.

Services revenue consists of contract manufacturing and quality control services related to the Company's relationship with Dechra. In the three months ended June 30, 2018, services revenue was \$16,005 compared to nil for the three months ended June 30, 2017.

The gross margin percentage on the sales of goods and services was 72% in the three months ended June 30, 2018 compared to 67% in the three months ended March 31, 2017. The increase was mainly attributable to a more profitable customer mix in the current period.

The Company's revenue by category for the six months ended June 30, 2018 and 2017 is summarized in the table below:

Six months ended June 30,	2018	2017	Change	% Change
License	\$ -	\$ 670,725	\$ (670,725)	-100.0%
Royalty	22,314	3,355	18,959	565.1%
Sales of goods and services	166,389	216,826	(50,437)	-23.3%
Total Revenue	\$ 188,703	\$ 890,906	\$ (702,203)	-78.8%

License revenue in the six months ended June 30, 2017 consists of an upfront payment of USD \$500,000 received from Dechra upon signing the License Agreement.

Royalty revenue in the six months ended June 30, 2018 increased by 565% to \$22,314 compared to \$3,355 in the six months ended June 30, 2017. Royalty payments from Dechra did not commence until Q2, 2017 and since that time, Dechra has continued to roll out the Vetradent product line to its North American veterinarian customer base.

Revenue from the sales of goods and services (bluestem, StrixNB, contract manufacturing and contract quality control services) in the six months ended June 30, 2018 was \$166,389, a decrease of 23% compared to \$216,826 in the six months ended June 30, 2017. During the six months ended June 30, 2017, the Company had not yet fully transitioned the licensure of its StrixNB technology to Dechra. StrixNB product revenue in the six months ended June 30, 2017 was \$94,663.

Services revenue consisting of contract manufacturing and quality control services related to the Company's relationship with Dechra in the six months ended June 30, 2018 was \$40,787 compared to nil for the six months ended June 30, 2017.

The gross margin percentage on the sales of goods and services was 62% in the six months ended June 30, 2018 compared to 68% in the three months ended March 31, 2017. The decrease was mainly attributable to an inventory obsolescence provision taken in the current period partially offset by a more profitable customer mix in the current period.

General and Administration Expenses

General and administration expenses include those costs not directly related to research and development. These include expenses associated with management and administrative staff compensation, commercialization activities and professional fees such as legal, audit, and investor relations.

The changes in general and administration expenditures by category for the three months ended June 30, 2018 and 2017 are reflected in the following table:

KANE BIOTECH INC.

Management Discussion and Analysis

Three months ended June 30,	2018	2017	Change	% Change
Compensation related costs	\$ 321,898	\$ 366,844	\$ (44,946)	-12.3%
Business development costs	161,474	124,235	37,239	30.0%
Legal costs	96,099	101,481	(5,382)	-5.3%
Other administration costs	68,889	87,483	(18,594)	-21.3%
General and administration expenses	\$ 648,360	\$ 680,043	\$ (31,683)	-4.7%

Lower compensation related costs in the three months ended June 30, 2018 compared to the three months ended June 30, 2017 are primarily due to higher base salaries and short-term compensation expenses partially offset by lower long-term compensation expenses.

Higher business development costs in the three months ended June 30, 2018 compared to the three months ended June 30, 2017 are primarily due to higher spending on investor relations costs as well as costs incurred in the current period related to the Company's listing on the OTCQB Venture Market.

Lower legal costs in the three months ended June 30, 2018 compared to the three months ended June 30, 2017 are primarily due to a lower need for general legal counsel services in the current period partially offset by legal costs incurred in the current period related to the Nestle lawsuit.

Lower other administration costs in the three months ended June 30, 2018 compared to the three months ended June 30, 2017 is primarily due to external accounting costs that were incurred in the comparative period having been replaced with the costs of a full time Chief Financial Officer (accounted for in Compensation related costs) during the current period.

The changes in general and administration expenditures by category for the six months ended June 30, 2018 and 2017 are reflected in the following table:

Six months ended June 30,	2018	2017	Change	% Change
Compensation related costs	\$ 696,583	\$ 693,148	\$ 3,435	0.5%
Business development costs	289,357	385,025	(95,668)	-24.8%
Legal costs	240,909	179,043	61,866	34.6%
Other administration costs	130,806	173,212	(42,406)	-24.5%
General and administration expenses	\$ 1,357,655	\$ 1,430,428	\$ (72,773)	-5.1%

Higher compensation related costs in the six months ended June 30, 2018 compared to the six months ended June 30, 2017 are primarily due to higher base salaries and short-term compensation expenses partially offset by lower long-term compensation and Board of Director compensation expenses.

Lower business development costs in the six months ended June 30, 2018 compared to the six months ended June 30, 2017 are primarily due to decreased spending on bluestem marketing programs and the elimination of marketing spending on StrixNB once it was licensed to Dechra in Q1, 2017 partially offset by higher spending on investor relations costs as well as costs incurred in the current period related to the Company's listing on the OTCQB Venture Market.

Higher legal costs in the six months ended June 30, 2018 compared to the six months ended June 30, 2017 are primarily due to legal expenses related to the Nestle lawsuit in the current period partially offset by legal expenses in the comparative period related to the Dechra License Agreement and overall higher general legal expenses in the comparative period.

Lower other administration costs in the six months ended June 30, 2018 compared to the six months ended June 30, 2017 are primarily due to external accounting costs that were incurred in the comparative period having been replaced with the costs of a full time Chief Financial Officer (accounted for in Compensation related costs) during the current period as well as lower auditing, information technology and communication expenditures in the current period than in the comparative period.

KANE BIOTECH INC.

Management Discussion and Analysis

Research and Development Expenses

Research and development expenses are associated with the Company's research and development programs. The Company is in the development and commercialization stage and devotes a significant portion of its financial resources to research and market-ready product development activities

The changes in research and development expenses by category for the three months ended June 30, 2018 and 2017 are reflected in the following table:

Three months ended June 30,	2018	2017	Change	% Change
Compensation related costs	\$ 96,609	\$ 84,852	\$ 11,757	13.9%
Contract research and scientific consulting	17,596	22,616	(5,020)	-22.2%
Patent related costs and other intangibles expensed	28,069	28,605	(536)	-1.9%
Other research costs	36,551	50,258	(13,707)	-27.3%
Government assistance	(55,469)	(62,385)	6,916	-11.1%
Research expenses	\$ 123,356	\$ 123,946	\$ (590)	-0.5%

Higher compensation related costs in the three months ended June 30, 2018 compared to the three months ended June 30, 2017 are due primarily to an increase in staffing to support increased research activities as well as an increase in short-term compensation expense partially offset by a decrease in long-term compensation expense.

Lower contract research and scientific consulting costs in the three months ended June 30, 2018 compared to the three months ended June 30, 2017 is primarily due to a reduced need for external contract research services.

Lower other research costs in the three months ended June 30, 2018 compared to the three months ended June 30, 2017 are due mainly to lower royalty fees expense partially offset by higher consumables costs in the current period compared to the previous period.

Lower government assistance recorded in the three months ended June 30, 2018 compared to the three months ended June 30, 2017 is the result of the Company receiving lower National Research Council Canada (NRC) Industrial Research Assistance Program (IRAP) grant funding in the current period compared to the grant funding it received in the comparative period.

The changes in research and development expenses by category for the six months ended June 30, 2018 and 2017 are reflected in the following table:

Six months ended June 30,	2018	2017	Change	% Change
Compensation related costs	\$ 186,463	\$ 137,326	\$ 49,137	35.8%
Contract research and scientific consulting	118,112	131,054	(12,942)	-9.9%
Patent related costs and other intangibles expensed	98,567	55,175	43,392	78.6%
Other research costs	84,910	97,497	(12,587)	-12.9%
Government assistance	(131,101)	(88,355)	(42,746)	48.4%
Research expenses	\$ 356,951	\$ 332,697	\$ 24,254	7.3%

Higher compensation related costs in the six months ended June 30, 2018 compared to the six months ended June 30, 2017 are due primarily to an increase in staffing to support increased research activities as well as an increase in short-term compensation expense partially offset by a decrease in long-term compensation expense.

Lower contract research and scientific consulting costs in the six months ended June 30, 2018 compared to the six months ended June 30, 2017 reflects a reduced need for external contract research and scientific consulting services.

Higher patent related costs and other intangibles expensed in the six months ended June 30, 2018 compared to the six months ended June 30, 2017 are due primarily to patent legal counsel expenses incurred in the current period in support of the Nestle lawsuit.

KANE BIOTECH INC.

Management Discussion and Analysis

Lower other research costs in the six months ended June 30, 2018 compared to the six months ended June 30, 2017 are due mainly to lower royalty fees expense partially offset by higher consumables and travel costs in the current period compared to the previous period.

Higher government assistance recorded in the six months ended June 30, 2018 compared to the six months ended June 30, 2017 is the result of the Company receiving higher National Research Council Canada (NRC) Industrial Research Assistance Program (IRAP) grant funding in the current period compared to the grant funding it received in the comparative period.

Finance Costs (Income)

The change in finance costs (income) for the three months ended June 30, 2018 and 2017 are reflected in the following table:

Three months ended June 30,	2018	2017	Change
Finance income	\$ (98)	\$ (55)	(43)
Finance expense	403	58,849	(58,446)
Foreign exchange loss, net	1,349	340	1,009
Net finance costs	\$ 1,654	\$ 59,134	\$ (57,480)

Lower finance expense in the three months ended June 30, 2018 compared to the three months ended June 30, 2017 is due primarily to convertible note accretion expense in the comparative period and costs related to the short-term bridge loan that was entered in to on June 23, 2017. The convertible note and bridge loan were paid off on July 21, 2017.

The change in finance costs (income) for the six months ended June 30, 2018 and 2017 are reflected in the following table:

Six months ended June 30,	2018	2017	Change
Finance income	\$ (139)	\$ (103)	(36)
Finance expense	930	86,407	(85,477)
Foreign exchange loss, net	1,597	(597)	2,194
Net finance costs	\$ 2,388	\$ 85,707	\$ (83,319)

Lower finance expense in the six months ended June 30, 2018 compared to the six months ended June 30, 2017 is due primarily to convertible note accretion expense in the comparative period and costs related to the short-term bridge loan that was entered in to on June 23, 2017. The convertible note and bridge loan were paid off on July 21, 2017.

Loss and Comprehensive Loss

The losses and comprehensive losses for the three months and six months ended June 30, 2018 and 2017 are reflected in the following tables:

Three months ended June 30,	2018	2017	Change
Loss and comprehensive loss	\$ (701,714)	\$ (790,549)	(88,835)
Basic and diluted loss per share	\$ (0.01)	\$ (0.02)	(0.01)

KANE BIOTECH INC.

Management Discussion and Analysis

Six months ended June 30,	2018	2017	Change
Loss and comprehensive loss	\$ (1,591,511)	\$ (1,028,243)	\$ 563,268
Basic and diluted loss per share	\$ (0.02)	\$ (0.02)	\$ 0.00

LIQUIDITY AND CAPITAL RESOURCES

Since inception, the Company has primarily financed its operations from revenue, public and private sales of equity, the exercise of warrants, loans and convertible notes, government grants and tax credits. As at June 30, 2018, the Company had cash of \$342,156 compared with \$258,259 at June 30, 2017.

Cash used in operating activities

Cash used in operating activities for the three months ended June 30, 2018 was \$870,710 compared to \$669,107 for the three months ended June 30, 2017. Cash used in operating activities for the six months ended June 30, 2018 was \$1,583,327 compared to \$729,581 for the six months ended June 30, 2017. In Q1, 2017, the Company received the \$500,000 USD initial payment from Dechra.

Cash from financing activities

There was no cash provided by financing activities during the three months and six months ended June 30, 2018 compared to \$400,000 in the three months and six months ended June 30, 2017. In Q2, 2017, the Company received a loan in the amount of \$400,000 from Individual Investment Corporation, an arm's length third-party lender.

Cash used in investing activities

Cash used in investing activities during the three months ended June 30, 2018 was \$31,962 compared to \$52,187 during the three months ended June 30, 2017 reflecting lower spending on new patents in the current period. Cash used in investing activities during the six months ended June 30, 2018 was \$50,240 compared to \$151,458 during the six months ended June 30, 2017 reflecting lower spending on both new equipment and new patents in the current period.

The Company continues to seek additional licensing and distribution partners for its various products and technologies currently in development. This in combination with ongoing royalties and potential milestone payments associated with its existing licensing agreement with Dechra will provide increasing liquidity in the future. The Company also intends to seek maximization of its use of government grant programs in order to offset some of its research costs.

However, it is possible that these sources of cash inflows will not be sufficient to entirely fund the Company's planned research activities and administration costs in 2018. If that is the case, the Company will consider financing alternatives including those used in the past such as private placements and debt financing to raise the necessary capital it requires to fund ongoing operations.

The Company manages its operational spending and determines its future financing requirements through a process of budgeting and ongoing cash flow forecasting.

Shares, options, and warrants

	August 21, 2018	June 30, 2018	December 31, 2017
Common shares issued and outstanding	80,113,536	80,113,536	80,113,536
Options outstanding	4,854,000	4,854,000	3,808,000
Warrants outstanding	38,004,997	34,504,997	35,304,997

A summary of the Company's share capital may be found in Note 9 of the accompanying financial statements.

KANE BIOTECH INC.

Management Discussion and Analysis

CONTRACTUAL OBLIGATIONS

The Company periodically enters into long-term contractual agreements for the licensing of technologies as well as the lease of facilities, equipment and certain purchased services. The following table presents commitments arising from agreements currently in force over the next five years.

	Payments due by Period							
	Within 1 year		2-3 years		4-5 years		Total	
Facility lease agreements	\$	51,681	\$	104,258	\$	-		\$
Accounts payable and accrued liabilities		540,009		-		-		540,009
	\$	591,690	\$	104,258	\$	-	\$	695,947
Licence maintenance fees (USD)	\$	10,000	\$	20,000	\$	20,000	\$	50,000

GUARANTEES

The Company periodically enters into research and licence agreements with third parties that include indemnification provisions customary in the industry. These guarantees generally require the Company to compensate the other party for certain damages and costs incurred as a result of claims arising from research and development activities undertaken on behalf of the Company. In some cases, the maximum potential amount of future payments that could be required under these indemnification provisions could be unlimited. These indemnification provisions generally survive termination of the underlying agreement. The nature of the indemnification obligations prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay. Historically, the Company has not made any indemnification payments under such agreements and no amount has been accrued in the accompanying financial statements with respect to these indemnification obligations.

OFF-BALANCE SHEET ARRANGEMENTS

The Company does not have any off-balance sheet arrangements.

CONTROLS

As a result of the Company's limited administrative staffing levels, internal controls which rely on segregation of duties in many cases are not appropriate or possible. Due to resource constraints and the present stage of the Company's development, the Company does not have sufficient size and scale to warrant the hiring of additional staff to correct this potential weakness at this time. To help mitigate the impact of this potential weakness, the Company is highly reliant on the performance of compensating procedures and senior management's review and approval.

As a TSX-Venture Exchange issuer, the Company is not required to certify the design and evaluation of the Company's disclosure controls and procedures (DC&P) and internal controls over financial reporting (ICFR), and as such has not completed such an evaluation.

Investors should be aware that inherent limitations on the ability of certifying officers of a venture issuer to design and implement on a cost-effective basis DC&P and ICFR as defined in NI 52-109 may result in additional risks to the quality, reliability, transparency and timeliness of interim and annual filings and other reports provided under securities legislation.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The preparation of financial statements in conformity with International Financial Reporting Standards ("IFRS") requires the Company to select from possible alternative accounting principles and to make estimates and assumptions that determine the reported amounts of assets and liabilities at the balance sheet date and reported costs and expenditures during the reporting

KANE BIOTECH INC.

Management Discussion and Analysis

period. Management believes that the estimates and assumptions upon which the Company relies are reasonable based upon information available at the time these estimates and assumptions are made. Estimates and assumptions may be revised as new information is acquired and are subject to change.

In addition to the going concern assumption described above, management believes that its most critical accounting policies and estimates relate to the following areas, with reference to notes contained in the accompanying financial statements:

Research and development costs

The Company's accounting policy over research and development costs may be found in Note 3(f)(i) in the Company's financial statements. Research expenditures are expensed as incurred. Development expenditures are deferred when they meet the criteria for capitalization in accordance with IFRS and the future benefits could be regarded as being reasonably certain. No development expenditures have been capitalized to date and there are no plans to capitalize development expenditures in the foreseeable future. Related Scientific Research & Experimental Development (SR&ED) investment tax credits are accounted for as a reduction to research and development expenditures in the period that they are earned and only to the extent they are refundable. Non-refundable SR&ED investment tax credits are not recorded in the financial statements as there is not assurance at this time there will be sufficient taxable income in the future to utilize those tax credits.

Patents and trademarks

The Company's accounting policy over patents and trademarks may be found in Notes 3(f)(ii) in the Company's financial statements. Patents and trademarks are reviewed for impairment on an ongoing basis whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If any such indication exists, then the asset's recoverable amount is estimated. An impairment exists when the carrying value of an asset exceeds its recoverable amount, which is the higher of its fair value less costs to sell or its value in use. The fair value less costs to sell calculation is based on available data from observable market prices, less incremental costs. The value in use calculation is based on a discounted cash flow model. These calculations require the use of estimates and forecasts of future cash flows. Qualitative factors, including market size and market growth trends, strength of customer demand and degree of variability in cash flows, as well as other factors, are considered when making assumptions regarding future cash flows and the appropriate discount rate. A change in any of the significant assumptions of estimates used to evaluate the underlying assets could result in a material change to the results of operations.

Impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed, to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of amortization, if no impairment had been recognized. Write-downs as a result of impairment are recognized in research expense in the statement of comprehensive loss.

Stock-based compensation

The Company's accounting policy over stock-based compensation may be found in Notes 3(h)(ii) and 9(c) in the Company's financial statements. Where the Company issues warrants and stock options (to its employees, directors and officers), a fair value is derived using the Black-Scholes pricing model. The application of this pricing model requires Management to make assumptions regarding several variables, including the expected life of the options and warrants, the price volatility of the Company's stock over a relevant timeframe, the determination of a relevant risk-free interest rate and an assumption regarding the Company's dividend policy in the future.

A summary of all the Company's significant accounting policies and estimates may be found in Note 3 to the financial statements.